The Minute Molecular Diagnostic test is differentiated from other COVID-19 tests:
Asymptomatic Testing - Ability to test for COVID-19 in both symptomatic and asymptomatic patients
Qualitative Report - Positive, negative or invalid
Easy to Use - Designed to be CLIA waived for point-of-care
Flexible Sample Type - Nasal swab, saliva, nasopharyngeal, UTM/VTM
Time to Result - Approximately 15 minutes
Accuracy - Lab quality quantitative PCR results
Sample-to-result in approximately 15 minutes
One cartridge for multiple test targets (Flu A/B and SARS-CoV-2 in development) collected from a single sample
Quantitative PCR / Central lab accuracy
Easy to Use
Designed to be CLIA waived for point-of-care
Connect via the cloud
Test Menu In Development
SARS-CoV-2 test results are for the identification of SARS-CoV-2 RNA. The SARS-CoV-2 RNA is generally detectable in upper respiratory specimens during the acute phase of infection. Positive results are indicative of the presence of SARS-CoV-2 RNA; clinical correlation with patient history and other diagnostic information is necessary to determine patient infection status.
HIV Viral Load
Measurement of blood plasma HIV-1 RNA concentration ("viral load") using nucleic acid-based molecular diagnostic assays is the standard of care in many areas of the world with access to antiretroviral therapy (ART). Untreated HIV-1 infection is characterized by high-level viral production and CD4 T-cell destruction progressing, despite an often lengthy clinical latency period, to significant net loss of CD4 T cells and AIDS.
DASH CT/NG/TV is a ready-to use test which contains all the necessary reagents for Real-Time PCR assay. The test is designed for the diagnosis of Chlamydia trachomatis, Neisseria gonorrhoeae and/or Trichomonas vaginalis in human urine specimens or vaginal swabs to aid in the assessment of infections caused by these sexually transmitted bacteria.
Flu A, Flu B, CoV-2
Results are for the simultaneous detection and differentiation of SARS-CoV-2, influenza A virus, and influenza B virus in clinical specimens and is not intended to detect influenza C virus. SARS-CoV-2, influenza A, and influenza B RNA identified by this test are generally detectable in upper respiratory specimens during the acute phase of infection. Positive results are indicative of the presence of the identified virus, but do not rule out bacterial infection or co-infection with other pathogens not detected by the test.
The DASH HCV Genotype II is an in vitro reverse transcription-polymerase chain reaction (RT-PCR) assay for the qualitative identification of hepatitis C virus (HCV) genotypes 1-6 in whole blood plasma, or serum from individuals chronically infected with HCV.